EFFICACY OF NILOTINIB IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA

Sajid Ali Sajid Ali,Kausar Bano Kausar Bano,Muhammad Akram Et Al Muhammad Akram Et Al,Tahir Mehmood Tahir Mehmood

doi:10.37723/jumdc.v10i4.78

Abstract

ABSTRACT:MATERIAL AND METHODS: This study was conducted on 92 diagnosed cases of chronic myeloid leukemia at Department of Oncology, Jinnah Hospital Lahore from August 2016 to January 2017. Patients from either gender, between the ages of 20 to 60 years were included in the study while patients having diabetes and end stage renal disease with glomerular ﬁltration rate less than 15 ml/min were excluded. Nilotinib treatment with the standard dose (300 mg twice daily) was given to patients with chronic phase of chronic myeloid leukemia (CP-CML). Patients were monitored as recommended by the current treatment guidelines. Treatment outcome of CP-CML in terms of eﬃcacy was assessed at the end of 6 months of treatment.OBJECTIVE: To determine the eﬃcacy of nilotinib in patients of chronic myeloid leukemia, chronic phase, in terms of detection of BCR-ABL by FISH method. RESULT: The mean age of the patients was 38.84 ± 11.67 years, with male to female ratio of 1.04:1. The mean PH value of the patients was 17.05 ± 18.53 and eﬃcacy was achieved in 36 (39.13%) patients. CONCLUSION: The eﬃcacy of nilotinib was achieved in signiﬁcant number of CML patients.

Highlights

Chronic myeloid leukemia (CML) defined as monoclonal myeloproliferative hematological disorder, because of the neoplastic change of the crude hematopoietic undifferentiated cells
The results of this study demonstrated that 17 male and 19 female patients accomplished finish sub-atomic reaction (CMR)
The results showed that 23 patients (≤ 40 years of age ) accomplished finish atomic reaction (CMR), likewise 13 patients (>40 years of age) accomplished finish sub-atomic reaction (CMR), which is statistically insignificant with p-value = 0.191

Summary

Introduction

Chronic myeloid leukemia (CML) defined as monoclonal myeloproliferative hematological disorder, because of the neoplastic change of the crude hematopoietic undifferentiated cells. These juvenile myeloid antecedent cells isolate and involve the bone marrow and spleen[1,2]. Introduction of second era TKIs, nilotinib, appeared to be more compelling than imatinib as first line treatment in accomplishing critical endpoints as a complete cytogenetic response (CCyR), i.e. the nonattendance of Ph+ cells in blood and bone marrow and a Noteworthy major molecular response (MMR), i.e. the close nonappearance of BCR-ABL combination mRNA transcripts

Methods

Results

Conclusion